Aeterna Zentaris Announces Replacement At the Market Issuance Program
April 27 2017 - 8:15PM
Business Wire
Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the “Company”)
announced today that it has entered into a new At Market Issuance
Sales Agreement, dated April 27, 2017 (the “New ATM Sales
Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”) and
that it has filed with the Securities and Exchange Commission (the
“SEC”) a prospectus supplement (the “Prospectus Supplement”)
related to sales and distributions of up to a maximum of 2,240,000
Common Shares through “at-the-market” (“ATM”) issuances on the
NASDAQ Stock Market, up to an aggregate amount of $6,944,000 under
the New ATM Sales Agreement. Wainwright will act as sales agent for
any sales made under the new ATM program. The Common Shares will be
sold at market prices prevailing at the time of the sale of the
Common Shares, and, as a result, prices may vary.
The New Sales Agreement and the Prospectus Supplement supersede
and replace the Company’s prior At Market Issuance Sales Agreement
entered into in April 2016 as well as its recently filed prospectus
supplement dated March 28, 2017. Since April 1, 2016, the Company
has issued approximately 2.3 million Common Shares and raised gross
proceeds of approximately $7.8 million under its previous Sales
Agreement with Wainwright, of which approximately 600,000 Common
Shares raising gross proceeds of approximately $1.8 million were
issued and sold under the March 28, 2017 prospectus supplement.
The Prospectus Supplement supplements the base prospectus
included in the Company’s replacement shelf Registration Statement
on Form F-3, as amended (File No. 333-216853) (the “2017 Shelf
Registration Statement”), which was declared effective by the SEC
on April 27, 2017. The 2017 Shelf Registration Statement and the
Prospectus Supplement are available on the SEC's website
(www.sec.gov). Alternatively, Wainwright will provide copies of
these documents upon request by contacting H.C. Wainwright &
Co., LLC, 430 Park Avenue, 4th Floor, New York, NY 10022 at
placements@hcwco.com.
This press release does not and shall not constitute an offer to
sell or the solicitation of an offer to buy any of the Common
Shares, nor shall there be any sale of the Common Shares in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We recently completed Phase 3 studies of two internally developed
compounds. The focus of our business development efforts is the
acquisition of licenses to products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
non-U.S. territories where such out-licensing would enable us to
ensure development, registration and launch of our product
candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and
commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value
to our shareholders, employees and the medical providers and
patients who will benefit from our products. For more information,
visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170427007012/en/
Aeterna Zentaris Inc.Philip A. Theodore, 843-900-3223Senior Vice
Presidentir@aezsinc.com
Aeterna Zentaris (TSX:AEZS)
Historical Stock Chart
From Apr 2024 to May 2024
Aeterna Zentaris (TSX:AEZS)
Historical Stock Chart
From May 2023 to May 2024